53 results about "Minimum bactericidal concentration" patented technology

The present invention provides blue coloured aqueous dispersion of silver nanoparticles and process for preparation thereof. The present invention also provides compositions comprising blue coloured dispersion of silver nanoparticles. The blue coloured aqueous dispersion comprising silver nanoparticles wherein dispersion is characterized by—having plasmonic peaks in the range 330-335 nm and 650-720 nm combined with missing plasmonic peaks in the range 390 to 410 nm and 410-500 nm in UV-Vis spectrum,—the dispersion having silver nanoparticles of anisotropic shape with majority of particles (>65%) having equivalent diameter in range of 0.5 to 6 nm,—Molar extinction coefficient greater than 10.1 preferably in the range of 10.1 to 15.7 mM−1cm−1 at wavelength of maximum absorption in the range of 650-720 nm,—Dispersion stability of at least 15 months,—Minimum Bactericidal Concentration (MBC) lower than 0.10 ppm preferably in the range of 0.055-0.099 ppm.

The invention provides united application of quercetin and antibacterials, and belongs to the field of antibacterials. The technical scheme adopted by the invention lies in that through the united medication of the quercetin and the antibacterials, synergistic antibacterial potency can be produced, the minimum inhibitory concentration and the minimum bactericidal concentration of the antibacterials can be reduced, and the quercetin and the antibacterials can be applied to preparation of new medicines and improvement of clinical effects of the antibacterials. The united application disclosed bythe invention has the beneficial effects that the united medication of the combination of the quercetin and the antibacterials can restrain the growth of bacteria, besides, the quercetin has the effect of synergistically resisting escherichia coli with the antibacterials, the antibacterials can restrain the growth of pathogenic bacteria at lower dosage, the antibacterial potency of the antibacterials is reinforced, the production of drug resistance of bacteria can be reduced, the effect of resisting bacterium infection is improved, the usage dosage of the antibacterials is reduced, and a compound recipe or a combination can be applied to prevention and treatment of bacterial infection diseases.

The invention provides a preparation method of a collagen-tea polyphenols antibacterial film. The method comprises the following steps: taking modified collagen solutions, respectively dissolving tea polyphenols having different qualities into the modified collagen solutions, and uniformly stirring to obtain collagen-tea polyphenols blending solutions with different concentrations; testing minimal inhibitory concentrations of the collagen-tea polyphenols blending solutions to obtain the minimal inhibitory concentrations of the tea polyphenols; testing minimum bactericidal concentrations of the collagen-tea polyphenols blending solutions which have the minimum inhibitory concentrations and of which the concentrations are more than the minimum inhibitory concentrations to obtain the minimum bactericidal concentrations of the tea polyphenols; carrying out vacuum degassing on the collagen-tea polyphenols blending solutions which have the minimum bactericidal concentrations and of which the concentrations are close to the minimum bactericidal concentrations, casting into a film, and removing the film to obtain the collagen-tea polyphenols antibacterial film. After the minimum inhibitory concentrations and the minimum bactericidal concentrations are obtained by using the preparation method disclosed by the invention, the preparation of the antibacterial film is guided; therefore, the method is simple and feasible.

The invention discloses a method for measuring plant pathogenic fungus inhibitory activity of lotus leaf total alkaloids and application of the plant pathogenic fungus inhibitory activity. The method includes: preparing spore suspension; preparing the lotus leaf total alkaloids; measuring the inhibitory effect of the lotus leaf total alkaloids; measuring the minimum bactericidal concentration of the lotus leaf total alkaloids; measuring the minimum inhibitory concentration of the lotus leaf total alkaloids. The method has the advantages that the fact that the lotus leaf total alkaloids have evident plant pathogenic fungus inhibitory activity is determined for the first time, the lotus leaf total alkaloids have the highest inhibitory activity on cucumber wilt fusarium, and the minimum bactericidal concentration and minimum inhibitory concentration of the lotus leaf total alkaloids are 160 microgram / mL; due to the fact that the lotus leaf resources in China are rich, extraction of the active alkaloids from the lotus leaves is low in cost, nontoxic and harmless; the lotus leaf total alkaloids are used for preventing and treating plant diseases, can be used as potential biological pesticide, and is promising in development and application prospect.

The invention discloses a deciquam and iodine compound disinfectant, which comprises the components by weight percent to prepare an intermediate product: 1.00-4.50 percent of iodine; 0.01-0.10 percent of potassium iodide, 30-50 percent of deciquam; 15-30 percent of surfactant; the balance of solubilizer; the intermediate product is obtained, and then water is added into the intermediate product for dilution so as to obtain the final product. The disinfectant has disinfection efficiency upon the bacteria, and the escherichia coli 8099 is taken as an example and the deciquam solution and the povidone iodine solution are taken as the comparison to conduct a sterilizing experiment to achieve the same disinfection efficiency (sterilizing rate is equal to or greater than 99.9 percent), the minimum concentration of deciquam and iodine of the invention is 25mg / L and 1,25mg / L respectively; the minimum concentration of deciquam in the deciquam solution is 63mg / L, and the minimum concentration of iodine in povidone iodine is 2.5mg / L, and the result indicates that the minimum sterilizing concentration of deciquam and iodine is remarkably reduced. The porcine parvovirus virus is taken as an example to indicate the disinfection efficiency upon the virus of the disinfectant, and the result indicates that the inactivation ratio of the disinfectant reaches over 99.9 percent, while the deciquam solution cannot kill the porcine parvovirus virus. The experiment indicates that iodine and deciquam of the compound disinfectant are subjected to complexing to form an entirety under the action of the surface active agent and the like, and the compound disinfectant has a strong synergistic effect.

The invention constructs procaryon recombinant plasmid of mouse beta-alexin 3 gene (Mbd-3) by gene engineering technology, comprising the steps of transferring the procaryon recombinant plasmid into engineering bacteria for induction efficient expression of mouse beta-alexin 3 polypeptide (MBD-3), extracting and purifying expression product and exonuclease to release active MBD-3 mature peptide. The invention detects the minimum inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of recombinant mouse beta-alexin 3 for resisting different mycelial fungus by mcroscale broth dilution method, proves that the recombinant mouse beta-alexin 3 polypeptide has function of resisting pathogenicity mycelial fungus so as to invent a novel medicament for curing mycotic infection.

The invention provides a preparation method of a collagen-lysozyme antibacterial film. The method comprises the following steps: taking modified collagen solutions, respectively dissolving lysozyme having different qualities into the modified collagen solutions, and uniformly stirring to obtain collagen-lysozyme blending solutions with different concentrations; testing minimal inhibitory concentrations of the collagen-lysozyme blending solutions with the different concentrations to obtain the minimal inhibitory concentration of the lysozyme; testing minimum bactericidal concentrations of the collagen-lysozyme blending solutions which have the minimum inhibitory concentrations and of which the concentrations are more than the minimum inhibitory concentrations to obtain the minimum bactericidal concentrations of the lysozyme; carrying out vacuum degassing on the collagen-lysozyme blending solutions which have the minimum bactericidal concentrations and of which the concentrations are close to the minimum bactericidal concentrations, casting into a film, and removing the film to obtain the collagen-lysozyme antibacterial film. After the minimum inhibitory concentrations and the minimum bactericidal concentrations are obtained by using the preparation method disclosed by the invention, the preparation of the antibacterial film is guided; therefore, the method is simple and feasible.

The invention discloses application of punicalagin in inhibiting growth of multi-drug resistant klebsiella pneumoniae. Punicalagin has a relatively good in-vitro killing effect on multi-drug resistantklebsiella pneumonia and can inhibit the growth of multi-drug resistant klebsiella pneumoniae, and the minimum bactericidal concentration is 3.6 mg / mL and the minimum bacteriostatic concentration is1.8 mg / mL. The invention provides the inhibiting effect of punicalagin on multi-drug resistant klebsiella pneumoniae, and the punicalagin has wide application value in the fields of medicine and the like.

The invention belongs to the technical field of veterinary drugs, and discloses an application of theaflavin in preparation of a drug for resisting avian pathogenic bacteria. The applicant discovers that theaflavin has the effects of inhibiting the growth of duck-origin chicken bacilli and avian pasteurella and killing the duck-origin chicken bacilli and avian pasteurella, the minimum inhibitory concentration of theaflavin to the duck-origin chicken bacilli is 128 mu g / ml, the minimum bactericidal concentration of theaflavin to the duck-origin chicken bacilli is 512 mu g / ml, the minimum inhibitory concentration of theaflavin to the avian pasteurella is 512 mu g / ml, and the minimum bactericidal concentration of theaflavin to the avian pasteurella is 512 mu g / ml. The toxic and side effects of vaccines, chemical drugs and antibiotics and potential food safety hazards are overcome, and wide application prospects and development values are achieved in the fields of food processing, medicine and breeding industry.

The invention discloses an application of citral in inhibiting growth of multi-drug resistant enterobacter cloacae. The citral can inhibit growth of multi-drug resistant enterobacter cloacae as the citral has relatively good in vitro killing action to multi-drug resistant enterobacter cloacae resisting cefazolin, cefotaxime, augmentin, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocyline, imipenem, piperacillin, azithromycin, macrodantin, sulfamethoxazole and nalidixic acid. The minimum bactericidal concentration is 1.6 mg / mL and the minimal inhibitory concentration is 1.0 mg / mL. The invention provides inhibiting action of citral to multi-drug resistant enterobacter cloacae and the citral has wide application value in the field of medicine.

The invention discloses a novel purpose of garlic volatile oil, in particular to an application of the garlic volatile oil in the preparation of a medicine for preventing and curing septica Bordetella. The experiments show that the minimum inhibitory concentration of the garlic volatile oil to the septica Bordetella is 125 mug / ml and the minimum bactericidal concentration is 250 Mug / mL.

The invention provides freesia hybrida essential oil with antibacterial activity as well as a preparation method and application of the freesia hybrida essential oil. The freesia hybrida essential oilis obtained by distilling and extracting freesia hybrida flowers in a blooming period by adopting a steam distillation method. The results of antibacterial and bacteriostatic drug sensitivity tests,a minimum inhibitory concentration (MIC) and a minimum bactericidal concentration (MBC) show that the essential oil has an antibacterial effect on bacteria (escherichia coli, bacillus subtilis, staphylococcus aureus, staphylococcus epidermidis and the like) and fungi (candida albicans, Shenkei sporidium, trichophyton rubrum, saccharomyces cerevisiae and the like), and presents a broad-spectrum inhibition effect on bacteria and fungi. Therefore, it is found that the freesia hybrida essential oil can be used for development and application of sterilization products and daily products.

The invention discloses an application of sanguinarine to restraining growth of staphylococcus lugdunensis. The sanguinarine has better in vitro destroying effects on medicine-resistant staphylococcuslugdunensis and can restrain the growth of the medicine-resistant staphylococcus lugdunensis, the minimum bactericidal concentration is 30 [mu]g / mL, and the minimal inhibitory concentration is 15[mu]g / mL. The invention provides the restraining effects of the sanguinarine on the staphylococcus lugdunensis, and the sanguinarine has high application value in the field of pharmaceuticals and the like.

The invention discloses application of luteolin in inhibition of growth of multi-drug-resistant providencia rettgeri. According to the invention, because the luteolin has a good in-vitro killing effect on multi-drug-resistant providencia rettgeri, the growth of the multi-drug-resistant providencia rettgeri can be inhibited; and the minimum bactericidal concentration is 30 to 250 microgram / mL and the minimum bacteriostatic concentration is 15 to 125 microgram / mL. The luteolin has an inhibiting effect on the multi-drug-resistant providencia rettgeri and thus has the great application value in the fields of medicines and the like.

The invention provides a common cephalanoplos herb trichloromethane extract. The common cephalanoplos herb trichloromethane extract is obtained by adding petroleum ether into common cephalanoplos herb crude powder or ethanol extract for extracting, then sequentially extracting extracts at corresponding solvent parts with trichloromethane, ethyl acetate, n-butyl alcohol and water, and collecting the extract at a trichloromethane part, so that the common cephalanoplos herb trichloromethane extract is obtained. The invention also provides application of the common cephalanoplos herb trichloromethane extract. The common cephalanoplos herb trichloromethane extract prepared by extracting by virtue of two systematic solvent processes has the minimum bactericidal concentration of 0.63mg / ml; and the experimental determination shows that the common cephalanoplos herb trichloromethane extract has the MIC value of 100mu g / ml and the MBC value of 400mu g / ml, and has better inhibiting and killing effects on a mycobacterium tuberculosis standard strain H37RV.

The invention provides a preparation method of a trametes tomentosa fermentation liquor ethyl acetate extract. The preparation method comprises the following steps: filtering out mycelia in trametes tomentosa fermentation liquor, extracting the mycelia for 4-6 times by using dichloromethane and methanol which are isovolumetrically mixed as an extraction solvent, combining extract solutions, and concentrating to obtain a mycelium extract; and carrying out vacuum concentration on the fermentation liquor after filtering out the mycelia to obtain concentrated fermentation liquor, mixing the mycelium extract with the concentrated fermentation liquor, extracting for 6-8 times by using ethyl acetate, merging the extract liquor, and carrying out vacuum concentration to obtain the trametes tomentosa fermentation liquor ethyl acetate extract. The trametes tomentosa ethyl acetate extract disclosed by the invention is highly sensitive to staphylococcus aureus and strong in bacteriostatic activity, the minimum bactericidal concentration of the trametes tomentosa ethyl acetate extract to staphylococcus aureus is 0.0975-0.04875 mg / mL, and the trametes tomentosa ethyl acetate extract can be used as a novel natural staphylococcus aureus bacteriostatic agent.

The invention belongs to the technical field of anti-helicobacter pylori treatment, and discloses application of DMAMA in preparation of a medicine for inhibiting helicobacter pylori in the oral cavity and the stomach. According to the invention, the minimum inhibitory concentration and the minimum bactericidal concentration of the medicine are determined through flat plate and bacterial suspension culture; the variation of bacterial quantities under the action of the medicine and the influence of the medicine on a bacterial toxicity level are determined; and cell safety detection is conducted. Aiming at the conditions that local drugs for effectively treating helicobacter pylori infection are lacked under existing conditions and the drug resistance rate of helicobacter pylori antibiotics is increased year by year, the pH sensitive characteristic of the DMAEM is combined for the first time, the DMAEM acts on the helicobacter pylori, and it is found that the DMAEM has a remarkable bactericidal effect on the helicobacter pylori and can effectively prevent and treat the helicobacter pylori infection. Meanwhile, the detection of the DMAEM has good biological safety. The DMAEM has relatively strong helicobacter pylori growth and proliferation resisting effects, so the adverse use of antibiotics is reduced, and the problems of antibiotic resistance and host flora disorder caused by antibiotic resistance are reduced.

The invention belongs to the technical field of veterinary drugs, and discloses application of theaflavin in preparation of anti-streptococcus suis drugs. The applicant discovers that the theaflavin has the effects of inhibiting the growth of streptococcus suis and killing the streptococcus suis, the minimum inhibitory concentration of the theaflavin to the streptococcus suis is 512 mu g / ml, the minimum bactericidal concentration of the theaflavin to the streptococcus suis is 2048 mu g / ml, the toxic and side effects of vaccines, chemical drugs and antibiotics and potential food safety hazards are overcome, and the theaflavin has wide application prospects and development values in the fields of food processing, medicine and breeding industry.

The invention provides a compound with antibacterial and bactericidal activities for strawberry angular leaf spot. The minimal inhibitory concentration (MIC) value for the strawberry angular leaf spot is 8 mu g / ml, and the minimum bactericidal concentration (MBC) value is 32 mu g / ml.

The invention discloses application of luteolin in inhibiting the growth of multi-drug resistant enterobacter cloacae. Luteolin has a good in-vitro killing effect on multi-drug resistant enterobactercloacae with resistance to cefazolin, cefotaxime, augmentin, meropenem, ofloxacin, levofloxacin, ciprofloxacin, cefoxitin, minocycline, imipenem, piperacillin, azithromycin, furantoin, sulfamethoxazole and nalidixic acid, can inhibit the growth of the multi-drug resistant enterobacter cloacae, and has a minimum bactericidal concentration of 0.5mg / mL and a minimum inhibitory concentration of 0.3mg / mL. The invention provides the inhibition effect of luteolin on the multi-drug resistant enterobacter cloacae, and has wide application value in the fields of medicine and the like.

The invention discloses application of vanillic acid in inhibiting growth of multi-drug-resistance staphylococcus aureus. The inhibition effect of the vanillic acid on humanized multi-drug-resistancestaphylococcus aureus is put forward based on the fact that the vanillic acid has a good in-vitro killing effect on humanized multi-drug-resistance staphylococcus aureus which is resistant to linezolid, trimethoprim, gentamicin, ciprofloxacin, penicillin, cefazolin, clindamycin, vancomycin, oxacillin and piperacillin, and can inhibit the growth of multi-drug-resistance staphylococcus aureus, wherein the minimum bactericidal concentration is 2.4 mg / mL, and the minimum inhibitory concentration is 0.3 mg / mL. By means of the vanillic acid, drug-resistance infection of multi-drug-resistance staphylococcus aureus can be effectively relieved or solved, the mortality is reduced, a new idea is put forward for inhibition of humanized multi-drug-resistance staphylococcus aureus, and the vanillic acidhas important practical significance.

The invention discloses application of vanillic acid in inhibiting the growth of multiple drug-resistant enterobacter cloacae. The method comprises the steps of determining the drug resistance of enterobacter cloacae to antibiotics by means of a paper sheet diffusion approach; determining that the minimum bactericidal concentration and minimum bacteriostatic concentration of the vanillic acid on multiple drug-resistant enterobacter cloacae are 1.6 mg / mL and 1.2 mg / mL respectively by means of a double dilution approach and an agar diffusion approach. It is disclosed that the non-antibiotic compound vanillic acid has an inhibition effect on multiple drug-resistant enterobacter cloacae, and the method has a high application value in the field of medicine.

The invention discloses an application of chelerythrine to restraining growth of staphylococcus lugdunensis. The chelerythrine has better in vitro destroying effects on medicine-resistant staphylococcus lugdunensis and can restrain the growth of the medicine-resistant staphylococcus lugdunensis, the minimum bactericidal concentration is 16 [mu]g / mL, and the minimal inhibition concentration is 7.8[mu]g / mL. The invention provides the restraining effects of the chelerythrine on the staphylococcus lugdunensis, and the chelerythrine has wide application value in the field of pharmaceuticals and thelike.

The invention discloses a compound which has inhibitory and bactericidal activity for phomopsis helianthi. The minimum inhibitory concentration (MIC) value of phomopsis helianthi is 0.5 microgram / mL, and the minimum bactericidal concentration (MBC) value of phomopsis helianthi is 0.2 microgram / mL.

The invention discloses an application of sanguinarine in inhibiting the growth of streptococcus pneumonia, according to the fact that the sanguinarine has a good in-vitro killing effect on streptococcus pneumonia, the sanguinarine can inhibit the growth of streptococcus pneumonia, the minimum bactericidal concentration is 31.2 mu g / mL, and the minimum inhibitory concentration is 15.6 mu g / mL. Thesanguinarine provided by the invention has an inhibition effect on pneumonia streptococcus, and has a wide application value in the fields of medicines and the like.